May 13, 2020 / 10:22 PM / 15 days ago

BRIEF-Mei Pharma And Kyowa Kirin Announce Updated Clinical Data From Early-Stage Follicular Lymphoma Study

May 13 (Reuters) - Kyowa Kirin Co Ltd:

* MEI PHARMA AND KYOWA KIRIN ANNOUNCE UPDATED CLINICAL DATA FROM THE PHASE 1B STUDY EVALUATING ME-401 ON AN INTERMITTENT SCHEDULE IN PATIENTS WITH FOLLICULAR LYMPHOMA AND OTHER B-CELL MALIGNANCIES; DATA TO BE FEATURED IN THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2020 VIRTUAL SCIENTIFIC PROGRAM

* MEI PHARMA INC - 83% OVERALL RESPONSE RATE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

* MEI PHARMA INC - ME-401 REMAINS GENERALLY WELL-TOLERATED WITH 7% DISCONTINUATION RATE DUE TO ADVERSE EVENTS IN THIS STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below